Main Article Content
Background. Nowadays, a search for diagnostically significant markers of aggressiveness of nonfunctioning pituitary adenomas remains relevant for further prognosis in the postoperative period. Nonfunctioning pituitary adenomas without pituitary hypersecretion are the forms of adenohypophysis tumors. In the general population, frequency of nonfunctioning pituitary adenomas is 50 cases per 1 million people. The purpose of the study is to determine the clinical diagnostic markers of tumor aggressiveness in patients with nonfunctioning pituitary adenomas and growth hormone deficiency, as well as their role in the severity of the neuroendocrine symptoms of the disease. Materials and methods. Under our supervision, there were 87 patients (44 men, 43 women), of them 31 with a verified diagnosis of nonfunctioning pituitary adenomas after transnasal hypophysectomy. Followup was from 1 to 3 years. Results. When patients were distributed in groups depending on histological description of nonfunctioning pituitary adenomas, those with chromophobe pituitary adenoma prevailed (77.5 %). Nonfunctioning pituitary adenomas in women were associated with obesity, primary and secondary hypothyroidism, secondary hypogonadism, syndrome of persistent galactorrheaamenorrhea (symptomatic and idiopathic forms), diabetes insipidus, empty sella syndrome and others. In men, nonfunctioning pituitary adenomas was accompanied by obesity, primary and secondary hypothyroidism, secondary hypogonadism, diabetes insipidus, gynecomastia. The scale developed to determine the markers of aggressiveness of nonfunctioning pituitary adenomas allowed identifying factors by 3 degrees and developing a set of measures to prevent the recurrence of tumor growth. Conclusions. Markers of aggressiveness of nonfunctioning pituitary adenomas are: young age of the patient, first symptoms of the disease, large tumor sizes, asymmetry and deformation of the pituitary gland, signs of tumor invasion into adjacent tissues/arteries/cavernous sinus, small cell and/or dark cell chromophobe adenomas, panhypopituitarism.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44.
Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro MD. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.
Mavromati M, Kuhn E, Agostini H, et al. Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2844-2852. doi: 10.1210/jc.2017-00202.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectionalstudy in the province of Liège, Belgium. J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75. doi: 10.1210/jc.2006-1668.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas:a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x.
Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro Md. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.
Khalimova ZYu, Kholova DS, Urmanova YuM, Alieva DA, Alimukhamedova GA, Nasirova KhK. Reproductive Function in Patients with Non-functioning Pituitary Adenoma According to the Register of the Republic of Uzbekistan. International Journal of Biomedicine. 2016;6(2):133-135 doi: 10.21103/Article6(2)_ShC1.